Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific, Inc. (TMO) is a global leader in providing science-based solutions, offering a wide range of products and services in the life sciences, analytical instruments, specialty diagnostics, and laboratory products sectors. The company's expansive portfolio includes scientific instruments, laboratory equipment, diagnostic consumables, and life science reagents, serving customers both in the United States and internationally.
Thermo Fisher operates through four distinct segments as of end-2023:
- Analytical Technologies (17% of sales): This segment focuses on providing high-quality instruments and software solutions for various scientific applications.
- Specialty Diagnostic Products (10% of sales): This segment specializes in offering diagnostic reagents and instruments for medical and research laboratories.
- Life Science Solutions (23% of sales): This segment provides reagents, instruments, and consumables used in biological research and drug development.
- Lab Products and Services (54% of sales): This is the largest segment, encompassing laboratory supplies, equipment, and contract research organization (CRO) services.
Thermo Fisher is continually expanding its offerings and capabilities through strategic partnerships, acquisitions, and technological innovation. The company's robust financial performance underscores its leadership in the industry, driven by consistent revenue growth, strong market presence, and a commitment to advancing scientific research and healthcare.
Recent achievements include technological advancements in analytical instruments, enhanced diagnostic solutions, and expanded biopharma services, reflecting Thermo Fisher's dedication to supporting life-saving research and diagnostic processes. Thermo Fisher remains committed to delivering high-quality products and services, fostering scientific breakthroughs, and maintaining its position at the forefront of scientific innovation.
Thermo Fisher Scientific (NYSE: TMO) has announced its Board of Directors has approved a quarterly cash dividend of $0.39 per common share. The dividend will be paid on January 15, 2025, to shareholders who are on record as of December 13, 2024.
Thermo Fisher Scientific (NYSE: TMO) reported Q3 2024 financial results with revenue of $10.60 billion, flat compared to $10.57 billion in Q3 2023. GAAP EPS was $4.25, down from $4.42, while adjusted EPS reached $5.28, compared to $5.69 in the prior year. The company's operating margin decreased to 17.3% from 17.6% year-over-year.
The quarter featured launches of innovative products, including the Iliad scanning transmission electron microscope and MagMAX Sequential DNA/RNA kit. Thermo Fisher raised its full-year adjusted EPS guidance to $21.35-$22.07 and maintained revenue guidance of $42.4-$43.3 billion.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has announced its plans to release third quarter 2024 financial results before the market opens on Wednesday, October 23, 2024. The company will hold a conference call at 8:30 a.m. EDT on the same day to discuss its financial performance and future expectations.
Investors can participate in the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S., using the access code 296868. The call will also be available for live listening on the "Investors" section of Thermo Fisher's website. A replay of the call will be accessible under "News, Events & Presentations" until Wednesday, November 6, 2024.
Thermo Fisher Scientific (NYSE: TMO) hosted its 2024 Investor Day, showcasing its industry-leading businesses and proven growth strategy. The company highlighted its position in a $235 billion market with long-term growth of 4% to 6%. Thermo Fisher emphasized its high-impact innovation, customer partnerships, and unparalleled commercial engine.
The company's Practical Process Improvement (PPI) Business System was presented as a core element driving competitive advantage and financial performance. Thermo Fisher outlined its disciplined capital deployment approach, focusing on strategic M&A and returning capital to shareholders. The company projects long-term organic revenue growth of 7% to 9% and mid-teens adjusted EPS growth.
Thermo Fisher Scientific, the global leader in serving science, has announced that its chairman, president, and CEO, Marc N. Casper, will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference. The presentation is scheduled for Thursday, September 5, 2024, at 8:30 a.m. EDT.
Investors and interested parties can access a live webcast of the presentation through the Investors section of Thermo Fisher's official website, www.thermofisher.com. This event provides an opportunity for stakeholders to gain insights into the company's strategies, performance, and future outlook directly from its top leadership.
Thermo Fisher Scientific (NYSE: TMO) reported its Q2 2024 financial results, with revenue slightly declining 1% to $10.54 billion. Despite this, the company saw improvements in profitability, with GAAP diluted EPS increasing 15% to $4.04 and adjusted EPS rising 4% to $5.37. The company's GAAP operating margin expanded to 17.3% from 14.8% in Q2 2023.
Thermo Fisher launched several innovative products during the quarter, including new mass spectrometers and sustainable bioprocessing solutions. The company also expanded its clinical trial supply services and completed the acquisition of Olink, enhancing its protein research capabilities. Based on strong performance, Thermo Fisher raised its full-year 2024 guidance, projecting revenue between $42.4 to $43.3 billion and adjusted EPS of $21.29 to $22.07.
CytoReason, a leader in computational disease modeling, has secured $80 million in funding from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific. The investment will be used to expand disease models, grow proprietary data, and establish a US hub in Cambridge, Massachusetts. CytoReason's technology provides molecular-level insights and AI tools to help pharma companies make data-driven R&D decisions, improving the probability of phase 2 success.
The company has partnerships with six of the world's top ten pharma companies and has published numerous scientific articles in prestigious journals. This funding round highlights the growing importance of AI and data modeling in pharmaceutical R&D, with investors recognizing CytoReason's potential to revolutionize drug development processes.
Thermo Fisher Scientific (NYSE: TMO) has announced a quarterly cash dividend of $0.39 per common share. This dividend is payable on October 15, 2024, to shareholders who are on record as of September 13, 2024. The announcement was made by the company's Board of Directors as part of their regular dividend policy.
This move reflects Thermo Fisher's ongoing commitment to providing consistent returns to its shareholders, reinforcing investor confidence in the company's financial stability and future growth prospects.
Thermo Fisher Scientific (NYSE: TMO) is collaborating with the National Cancer Institute (NCI) to advance the myeloMATCH precision medicine clinical trial. This trial aims to accelerate research and treatment for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) using next-generation sequencing (NGS) technology. By quickly identifying genetic biomarkers in patients' bone marrow and blood, the trial aims to match patients to appropriate clinical studies. This approach could lead to more personalized and effective treatments, potentially increasing the survival rate for these aggressive cancers. The trial will deploy Thermo Fisher's Ion Torrent Genexus System, which offers next-day genomic testing and covers over 2,200 sites in North America.
Thermo Fisher Scientific (NYSE: TMO) has successfully completed its acquisition of Olink Holding AB (Nasdaq: OLK) for $3.1 billion. This strategic acquisition enhances Thermo Fisher's capabilities in the high-growth proteomics market, integrating Olink’s advanced proteomics solutions with Thermo Fisher's mass spectrometry and life sciences offerings.
The transaction was executed via a tender offer where Thermo Fisher's subsidiary, Orion Acquisition AB, acquired approximately 98.2% of Olink’s outstanding shares at $26.00 per share or ADS. The initial offering period expired on July 9, 2024, and a subsequent offering period will run until July 16, 2024.
Post-acquisition, Olink will be delisted from Nasdaq and deregistered, affecting the liquidity of remaining ADSs. Thermo Fisher aims to expedite scientific breakthroughs and deliver significant shareholder value through this acquisition.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
What does Thermo Fisher Scientific, Inc. specialize in?
What are the main segments of Thermo Fisher Scientific?
How much of Thermo Fisher's sales come from Lab Products and Services?
Where does Thermo Fisher Scientific operate?
What recent achievements has Thermo Fisher Scientific made?
What is Thermo Fisher Scientific's stock symbol?
How does Thermo Fisher Scientific support scientific research?
What types of products does Thermo Fisher Scientific offer?
What is Thermo Fisher's commitment to the healthcare industry?
What sets Thermo Fisher Scientific apart in its industry?
